Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on Next

(Sharecast News) - Analysts at Berenberg hiked their target price on retailer Next from 13,400.0p to 14,700.0p on Friday, citing upside risks to its Q2 estimates. Berenberg said Next's Q126 trading statement on 8 May brought the second upgrade to adjusted pre-tax profit guidance this year, on the back of four upgrades in each of the past two years. In its view, this "positive momentum" reflects the changing profile of Next and some growth angles that have emerged recently - as opposed to a time-limited self-help recovery, which was "more typical" for legacy retailers.

The German bank noted that Next's 1.3% adjusted pre-tax profit guidance upgrade for FY26E took into account the better performance than it had anticipated in Q1, but said it added nothing beyond its previous guidance for the remainder of the year.

"We see upside risk to our Q2 estimate of 4.9% total full-priced sales growth and to company guidance. Prior-year comparatives do not become more demanding until Q3," said Berenberg, which has a 'buy' rating on the stock.

"Our profit estimates are raised by 1-2% through the DCF, but we also now incorporate a 10% premium for management and the quality and defence profile of Next."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.